Commercialized biomarkers: new horizons in prostate cancer diagnostics
- PMID: 25711191
- DOI: 10.1586/14737159.2015.1011622
Commercialized biomarkers: new horizons in prostate cancer diagnostics
Abstract
Limitations with current clinical tools available for diagnosis and prognosis of prostate cancer (PCa) have resulted in overdiagnosis and costly overtreatment, which is affecting the outcomes and quality of life of men. The biotech industry is investing significant resources into developing more specific biomarkers for PCa detection and patient stratification that would greatly advance the decision-making processes behind PCa management and treatment. In this review, we focus on those biomarkers that have been translated into commercial tests available to clinicians. Since these tests aim to fill specific gaps during the decision-making process of PCa management, we have grouped them based on the clinical question they claim to address, that is, improved PCa screening, false-negative biopsy dilemma, prognostic tests following a positive biopsy and tests predicting relapse/metastases after surgery. We evaluate each test with respect to its development, platform, clinical validation, biomatrix, regulatory approval status and cost.
Keywords: clinical utility; commercialized prostate cancer tests; false-negative biopsy dilemma; patented biomarkers; prostate cancer screening.
Similar articles
-
Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.Eur Urol. 2011 Nov;60(5):1045-54. doi: 10.1016/j.eururo.2011.08.003. Epub 2011 Aug 25. Eur Urol. 2011. PMID: 21871709 Review.
-
Prognostic and predictive biomarkers in prostate cancer.Expert Rev Mol Diagn. 2015;15(12):1567-76. doi: 10.1586/14737159.2015.1110022. Epub 2015 Nov 7. Expert Rev Mol Diagn. 2015. PMID: 26548550 Review.
-
A novel algorithm for the prediction of prostate cancer in clinically suspected patients.Cancer Biomark. 2013;13(4):227-34. doi: 10.3233/CBM-130357. Cancer Biomark. 2013. PMID: 24240583
-
Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17. Eur Urol. 2011. PMID: 21601352 Clinical Trial.
-
[Update on the diagnosis of PCa in urine. The current role of urine markers].Arch Esp Urol. 2015 Apr;68(3):240-9. Arch Esp Urol. 2015. PMID: 25948797 Review. Spanish.
Cited by
-
Validation of potential RNA biomarkers for prostate cancer diagnosis and monitoring in plasma and urinary extracellular vesicles.Front Mol Biosci. 2023 Nov 30;10:1279854. doi: 10.3389/fmolb.2023.1279854. eCollection 2023. Front Mol Biosci. 2023. PMID: 38099195 Free PMC article.
-
Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research.Br J Cancer. 2022 Feb;126(3):331-350. doi: 10.1038/s41416-021-01610-8. Epub 2021 Nov 22. Br J Cancer. 2022. PMID: 34811504 Free PMC article. Review.
-
Integrating Serum Biomarkers into Prediction Models for Biochemical Recurrence Following Radical Prostatectomy.Cancers (Basel). 2021 Aug 19;13(16):4162. doi: 10.3390/cancers13164162. Cancers (Basel). 2021. PMID: 34439316 Free PMC article.
-
Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification.Eur Urol Open Sci. 2020 Oct 13;21:51-60. doi: 10.1016/j.euros.2020.08.007. eCollection 2020 Oct. Eur Urol Open Sci. 2020. PMID: 34337468 Free PMC article.
-
Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics.Metabolites. 2021 Mar 19;11(3):181. doi: 10.3390/metabo11030181. Metabolites. 2021. PMID: 33808897 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
